Continuous infusion of PGE2 is catabolic with a negative bone balance on both cancellous and cortical bone in rats.
It is well documented that intermittent PGE(2) treatment increases both trabecular and cortical bone mass. However, the effects of continuous PGE(2) administration remain undocumented. The aim of the study was to investigate the effects of continuous prostaglandin E(2) (PGE(2)) on different bone sites in skeletally mature rats. Six-month-old Sprague Dawley rats were treated with PGE(2) at 1 or 3 mg/kg/d continuously via infusion pump for 21 days. Two other groups of rats received PGE(2) at the same doses by intermittent (daily) subcutaneous injections and served as positive controls. Histomorphometry was performed on cancellous bone of the proximal tibial metaphysis and cortical bone of the tibial shaft. As expected, intermittent PGE(2) treatment increased both cancellous and cortical bone mass by stimulating bone formation at the cancellous, periosteal and endocortical bone surfaces. In contrast, continuous PGE(2) treatment decreased cancellous bone mass with bone resorption exceeding bone formation. In addition, continuous PGE(2) treatment increased endocortical and intracortical bone remodeling, inducing bone loss which was partially offset by stimulating periosteal expansion. We conclude that continuous PGE(2) treatment induces overall catabolic effects on both cancellous and cortical bone envelopes, which differs from intermittent PGE(2) treatment that is anabolic. Lastly, we speculate that superior bone mass may be achieved by co-treatment of continuous PGE(2) in combination with an anti-catabolic agent.
Tian
X Y
XY
Division of Radiobiology, University of Utah School of Medicine, Salt Lake City, UT 84108-1218, USA.
Zhang
Q
Q
Zhao
R
R
Setterberg
R B
RB
Zeng
Q Q
QQ
Ma
Y F
YF
Jee W
S S
SS
D000818:Animals; D001861:Bone Regeneration / Q000187:drug effects / Q000502:physiology; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology; D001862:Bone Resorption / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D015232:Dinoprostone / Q000633:toxicity*; D004334:Drug Administration Schedule; D005260:Female; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008660:Metabolism / Q000187:drug effects / Q000502:physiology; D010120:Oxytocics / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D013995:Time
D010120:Oxytocics; D015232:Dinoprostone